Paper Details

  1. Home
  2. Paper Details

Autoantibodies against type I IFNs in patients with critical influenza pneumonia.

Author: , AbelLaurent, Abelenda-AlonsoGabriela, AndreakosEvangelos, ArgaudLaurent, AydilloTeresa, Balsera-ManzaneroMaría, BastardPaul, BizienLucy, BrionesMarisa, CarratalaJordi, CasalegnoJean-Sebastien, CasanovaJean-Laurent, CastagnoliRiccardo, CobatAurélie, CorderoElisa, CupicAnastasija, DebetteStéphanie, Dominguez-PinillaNerea, EtzioniAmos, FerreresJosé, FerresMarcela, FeysSimon, FournetThomas, García-SalumTamara, García-SastreAdolfo, GervaisAdrian, GoavecKelian, Gonzalez-GranadoLuis I, HaerynckFilomeen, HannaSuhair, JavouheyEtienne, JouanguyEmmanuelle, KisandKai, KuCheng-Lung, KuoChen-Yen, LaurentEmilie, Le CorreNicole, Le VoyerTom, LeiWei-Te, ManryJeremy, MedinaRafael A, MeytsIsabelle, MiorinLisa, NotarangeloLuigi D, PadeyBlandine, PhilippotQuentin, PizzornoAndrés, PuelAnne, QueromesGregory, Retamar-GentilPilar, Rodríguez de CastroFelipe, Rodríguez-GallegoCarlos, Rosa-CalatravaManuel, RosainJérémie, Ruiz-HernandezJosé Juan, SakerKahina, Solé-ViolánJordi, Sánchez-CéspedesJavier, SärekannuKarita, TalGalit, TiberghienPierre, TriantafylliaVasiliki, Trouillet-AssantSophie, ValienteAdoración, VanderbekeLore, VankerMartti, WautersJoost, ZhangQian, ZinsMarie

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

Autoantibodies neutralizing type I interferons (IFNs) can lead to serious complications in patients with influenza pneumonia. This study identifies a significant prevalence of these antibodies in patients with critical influenza pneumonia, especially in those under 70 years old.
Paper Details　
Original Abstract of the Article :
Autoantibodies neutralizing type I interferons (IFNs) can underlie critical COVID-19 pneumonia and yellow fever vaccine disease. We report here on 13 patients harboring autoantibodies neutralizing IFN-α2 alone (five patients) or with IFN-ω (eight patients) from a cohort of 279 patients (4.7%) aged 6...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485705/

データ提供：米国国立医学図書館（NLM）

Autoantibodies Against Type I IFNs: A New Frontier in Critical Influenza Pneumonia

This study investigates the role of autoantibodies that neutralize type I interferons (IFNs) in critical influenza pneumonia, a severe form of the flu. Type I IFNs, a group of proteins that play a crucial role in the body's immune response to viral infections, are sometimes targeted by the body's own immune system, leading to the development of autoantibodies. The researchers studied a cohort of patients with critical influenza pneumonia and identified a significant number who had autoantibodies against type I IFNs. The study aimed to understand the prevalence and clinical implications of these autoantibodies in critical influenza pneumonia.

Autoantibodies Against Type I IFNs: A Potential Risk Factor for Critical Influenza

The study found that autoantibodies against type I IFNs were present in a significant proportion of patients with critical influenza pneumonia. These autoantibodies, by interfering with the body's ability to mount an effective immune response, may contribute to the severity of the illness. The study's findings underscore the importance of further investigation into the role of these autoantibodies in influenza infection and their potential implications for treatment.

Influenza: A Persistent Threat to Global Health

Influenza is a common respiratory illness that can cause significant morbidity and mortality. This research highlights the complexities of influenza infection, emphasizing the importance of understanding the factors that contribute to severe disease. It's crucial to get vaccinated against influenza every year, practice good hygiene, and seek medical attention promptly if you experience flu-like symptoms.

Dr. Camel's Conclusion

This research, like a camel caravan traversing the shifting sands of the influenza landscape, unveils the potential role of autoantibodies against type I IFNs in critical influenza pneumonia. The study's findings, like a shimmering oasis, highlight the complex interplay between the immune system and viral infections. It's a reminder that the journey towards better influenza prevention and treatment requires ongoing research and a commitment to public health measures.
Date :
  1. Date Completed 2022-09-20
  2. Date Revised 2023-05-16
Further Info :

Pubmed ID

36112363

DOI: Digital Object Identifier

PMC9485705

Related Literature

Article Analysis
・Effects of yellow fever vaccine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.